Baxter International Competitors

Baxter International (NYSE:BAX) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Valuation and Earnings

This table compares Baxter International and Abbott Laboratories' gross revenue, earnings per share (EPS) and valuation.

Abbott Laboratories has higher revenue and earnings than Baxter International. Baxter International is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

69.7% of Baxter International shares are held by institutional investors. Comparatively, 63.9% of Abbott Laboratories shares are held by institutional investors. 0.1% of Baxter International shares are held by company insiders. Comparatively, 1.7% of Abbott Laboratories shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Dividends

Baxter International pays an annual dividend of $0.98 per share and has a dividend yield of 1.3%. Abbott Laboratories pays an annual dividend of $1.44 per share and has a dividend yield of 1.3%. Baxter International pays out 29.6% of its earnings in the form of a dividend. Abbott Laboratories pays out 44.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Baxter International has raised its dividend for 4 consecutive years and Abbott Laboratories has raised its dividend for 48 consecutive years. Abbott Laboratories is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Recommendations

This is a breakdown of current recommendations for Baxter International and Abbott Laboratories, as reported by MarketBeat.com.

Baxter International currently has a consensus target price of $95.4118, suggesting a potential upside of 25.92%. Abbott Laboratories has a consensus target price of $115.3750, suggesting a potential upside of 5.59%. Given Baxter International's stronger consensus rating and higher probable upside, research analysts clearly believe Baxter International is more favorable than Abbott Laboratories.

Profitability

This table compares Baxter International and Abbott Laboratories' net margins, return on equity and return on assets.

Risk & Volatility

Baxter International has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500.

Summary

Abbott Laboratories beats Baxter International on 9 of the 17 factors compared between the two stocks.

Baxter International (NYSE:BAX) and Medtronic (NYSE:MDT) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Valuation and Earnings

This table compares Baxter International and Medtronic's gross revenue, earnings per share (EPS) and valuation.

Medtronic has higher revenue and earnings than Baxter International. Baxter International is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

69.7% of Baxter International shares are held by institutional investors. Comparatively, 79.9% of Medtronic shares are held by institutional investors. 0.1% of Baxter International shares are held by company insiders. Comparatively, 0.5% of Medtronic shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Dividends

Baxter International pays an annual dividend of $0.98 per share and has a dividend yield of 1.3%. Medtronic pays an annual dividend of $2.32 per share and has a dividend yield of 2.1%. Baxter International pays out 29.6% of its earnings in the form of a dividend. Medtronic pays out 50.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Baxter International has raised its dividend for 4 consecutive years and Medtronic has raised its dividend for 43 consecutive years. Medtronic is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Recommendations

This is a breakdown of current recommendations for Baxter International and Medtronic, as reported by MarketBeat.com.

Baxter International currently has a consensus target price of $95.4118, suggesting a potential upside of 25.92%. Medtronic has a consensus target price of $118.1538, suggesting a potential upside of 6.47%. Given Baxter International's higher probable upside, research analysts clearly believe Baxter International is more favorable than Medtronic.

Profitability

This table compares Baxter International and Medtronic's net margins, return on equity and return on assets.

Risk & Volatility

Baxter International has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500.

Summary

Medtronic beats Baxter International on 12 of the 18 factors compared between the two stocks.

Baxter International (NYSE:BAX) and Stryker (NYSE:SYK) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Institutional and Insider Ownership

69.7% of Baxter International shares are held by institutional investors. Comparatively, 71.0% of Stryker shares are held by institutional investors. 0.1% of Baxter International shares are held by company insiders. Comparatively, 6.8% of Stryker shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Baxter International and Stryker, as reported by MarketBeat.com.

Baxter International currently has a consensus target price of $95.4118, suggesting a potential upside of 25.92%. Stryker has a consensus target price of $221.44, suggesting a potential downside of 4.97%. Given Baxter International's stronger consensus rating and higher probable upside, research analysts clearly believe Baxter International is more favorable than Stryker.

Profitability

This table compares Baxter International and Stryker's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Baxter International and Stryker's gross revenue, earnings per share (EPS) and valuation.

Stryker has higher revenue and earnings than Baxter International. Baxter International is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Dividends

Baxter International pays an annual dividend of $0.98 per share and has a dividend yield of 1.3%. Stryker pays an annual dividend of $2.30 per share and has a dividend yield of 1.0%. Baxter International pays out 29.6% of its earnings in the form of a dividend. Stryker pays out 27.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Baxter International has raised its dividend for 4 consecutive years and Stryker has raised its dividend for 1 consecutive years. Baxter International is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Risk & Volatility

Baxter International has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500. Comparatively, Stryker has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500.

Summary

Stryker beats Baxter International on 13 of the 18 factors compared between the two stocks.

Intuitive Surgical (NASDAQ:ISRG) and Baxter International (NYSE:BAX) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Institutional and Insider Ownership

86.9% of Intuitive Surgical shares are owned by institutional investors. Comparatively, 69.7% of Baxter International shares are owned by institutional investors. 1.6% of Intuitive Surgical shares are owned by company insiders. Comparatively, 0.1% of Baxter International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings for Intuitive Surgical and Baxter International, as provided by MarketBeat.com.

Intuitive Surgical currently has a consensus price target of $718.2778, suggesting a potential downside of 0.11%. Baxter International has a consensus price target of $95.4118, suggesting a potential upside of 25.92%. Given Baxter International's stronger consensus rating and higher probable upside, analysts clearly believe Baxter International is more favorable than Intuitive Surgical.

Profitability

This table compares Intuitive Surgical and Baxter International's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Intuitive Surgical and Baxter International's gross revenue, earnings per share (EPS) and valuation.

Intuitive Surgical has higher earnings, but lower revenue than Baxter International. Baxter International is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Intuitive Surgical has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Comparatively, Baxter International has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500.

Summary

Intuitive Surgical beats Baxter International on 9 of the 14 factors compared between the two stocks.

Becton, Dickinson and (NYSE:BDX) and Baxter International (NYSE:BAX) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Dividends

Becton, Dickinson and pays an annual dividend of $3.16 per share and has a dividend yield of 1.4%. Baxter International pays an annual dividend of $0.98 per share and has a dividend yield of 1.3%. Becton, Dickinson and pays out 31.0% of its earnings in the form of a dividend. Baxter International pays out 29.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Becton, Dickinson and has increased its dividend for 49 consecutive years and Baxter International has increased its dividend for 4 consecutive years. Becton, Dickinson and is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Profitability

This table compares Becton, Dickinson and and Baxter International's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings for Becton, Dickinson and and Baxter International, as provided by MarketBeat.com.

Becton, Dickinson and currently has a consensus price target of $280.2857, suggesting a potential upside of 22.67%. Baxter International has a consensus price target of $95.4118, suggesting a potential upside of 25.92%. Given Baxter International's stronger consensus rating and higher probable upside, analysts clearly believe Baxter International is more favorable than Becton, Dickinson and.

Institutional and Insider Ownership

74.4% of Becton, Dickinson and shares are owned by institutional investors. Comparatively, 69.7% of Baxter International shares are owned by institutional investors. 0.1% of Becton, Dickinson and shares are owned by company insiders. Comparatively, 0.1% of Baxter International shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Becton, Dickinson and and Baxter International's revenue, earnings per share (EPS) and valuation.

Baxter International has lower revenue, but higher earnings than Becton, Dickinson and. Becton, Dickinson and is trading at a lower price-to-earnings ratio than Baxter International, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Becton, Dickinson and has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, Baxter International has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500.

Edwards Lifesciences (NYSE:EW) and Baxter International (NYSE:BAX) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, valuation, profitability and analyst recommendations.

Profitability

This table compares Edwards Lifesciences and Baxter International's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current recommendations and price targets for Edwards Lifesciences and Baxter International, as provided by MarketBeat.com.

Edwards Lifesciences presently has a consensus price target of $87.7222, indicating a potential upside of 3.57%. Baxter International has a consensus price target of $95.4118, indicating a potential upside of 25.92%. Given Baxter International's stronger consensus rating and higher probable upside, analysts plainly believe Baxter International is more favorable than Edwards Lifesciences.

Institutional & Insider Ownership

79.7% of Edwards Lifesciences shares are held by institutional investors. Comparatively, 69.7% of Baxter International shares are held by institutional investors. 1.5% of Edwards Lifesciences shares are held by company insiders. Comparatively, 0.1% of Baxter International shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Edwards Lifesciences and Baxter International's gross revenue, earnings per share (EPS) and valuation.

Edwards Lifesciences has higher earnings, but lower revenue than Baxter International. Baxter International is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Edwards Lifesciences has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Comparatively, Baxter International has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500.

Summary

Edwards Lifesciences beats Baxter International on 9 of the 14 factors compared between the two stocks.